Bill Maughan
Stock Analyst at Canaccord Genuity
(n/a)
# 4,325
Out of 4,789 analysts
14
Total ratings
12.5%
Success rate
-45.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bill Maughan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $26 | $4.43 | +486.91% | 2 | Aug 13, 2024 | |
| NKTX Nkarta | Maintains: Buy | $16 → $15 | $1.84 | +715.22% | 2 | May 10, 2024 | |
| FATE Fate Therapeutics | Maintains: Buy | $11 → $9 | $0.79 | +1,039.10% | 1 | May 10, 2024 | |
| IMCR Immunocore Holdings | Maintains: Hold | $63 → $67 | $29.67 | +125.82% | 3 | May 9, 2024 | |
| MRNA Moderna | Maintains: Hold | $91 → $106 | $28.35 | +273.90% | 3 | May 3, 2024 | |
| IPSC Century Therapeutics | Maintains: Buy | $22 → $24 | $0.48 | +4,942.02% | 1 | Mar 15, 2024 | |
| BCYC Bicycle Therapeutics | Reiterates: Buy | $60 | $8.49 | +606.71% | 1 | Feb 21, 2024 | |
| MRUS Merus | Initiates: Buy | $45 | $42.09 | +6.91% | 1 | Nov 2, 2023 |
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Buy
Price Target: $26
Current: $4.43
Upside: +486.91%
Nkarta
May 10, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $1.84
Upside: +715.22%
Fate Therapeutics
May 10, 2024
Maintains: Buy
Price Target: $11 → $9
Current: $0.79
Upside: +1,039.10%
Immunocore Holdings
May 9, 2024
Maintains: Hold
Price Target: $63 → $67
Current: $29.67
Upside: +125.82%
Moderna
May 3, 2024
Maintains: Hold
Price Target: $91 → $106
Current: $28.35
Upside: +273.90%
Century Therapeutics
Mar 15, 2024
Maintains: Buy
Price Target: $22 → $24
Current: $0.48
Upside: +4,942.02%
Bicycle Therapeutics
Feb 21, 2024
Reiterates: Buy
Price Target: $60
Current: $8.49
Upside: +606.71%
Merus
Nov 2, 2023
Initiates: Buy
Price Target: $45
Current: $42.09
Upside: +6.91%